Tenderwize
Back to tender search

Mepolizumab medicine discount agreements

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 100 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Mepolizumab, ATC R03DX09

60/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

58 / 100

Risk factors

No estimated value, volume, minimum purchase commitment, or demand information is provided, so the commercial opportuni...

The buyer may conduct European-wide procedures for exclusive rebate agreements, and the open-house contracts may end au...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Feb 28, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements for medicines containing mepolizumab, ATC R03DX09.
  • Contract period stated as 1 May 2025 to 30 April 2027, with agreements available for conclusion on the first day of each month.
Show full summary

Open-house, non-exclusive pharmaceutical rebate agreements for mepolizumab (ATC R03DX09) offered by AOK Rheinland-Pfalz/Saarland to all interested pharmaceutical companies meeting the stated medicinal-product requirements. There is no competitive selection or individual negotiation; uniform contract terms apply. Agreements may be concluded monthly during the maximum 24-month period, but may end early if replaced by exclusive agreements. No contract value is stated. Procurement documents were not provided for analysis.

Risks

No estimated value, volume, minimum purchase commitment, or demand information is provided, so the commercial opportuni...

The buyer may conduct European-wide procedures for exclusive rebate agreements, and the open-house contracts may end au...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • The participant must be a pharmaceutical company offering the relevant mepolizumab medicines.
  • Medicines must be authorised and marketable in Germany.
  • If the medicine is listed as marketable in the Lauer-Taxe, this is accepted as evidence.

Buyer

Lots (1)

LOT-0001

Mepolizumab Pharmaceutical Rebate Agreements

Non-exclusive open-house rebate agreements under Sections 130a(8) and 130c(1) SGB V for medicines containing mepolizumab, ATC R03DX09. Contracts are available to all interested pharmaceutical companies without a selection decision, use uniform non-negotiable conditions, and may be concluded from the first day of each month during the contract period. Medicines on the BfArM list for children's medicines under Section 35(5a) SGB V are excluded.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
12 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
165250-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy